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Timing still key to treating hypoxic ischaemic brain injury
Perinatal hypoxic ischaemic encephalopathy is a 
devastating disorder that aﬀ ects roughly two per 
1000 term infants despite modern obstetric care. The 
important breakthrough in clinical and experimental 
studies was that, in many cases, brain oxidative 
metabolism transiently recovers to normal for some 
hours even after severe hypoxia–ischaemia before 
then failing again.1,2 This observation suggested the 
hypothesis that exposure to low oxygen levels triggers 
active cell-death pathways that could be inhibited. The 
results of preclinical studies then showed that mild 
cerebral hypothermia started within around 6 h of 
birth, before the onset of delayed energy failure, and 
continued until resolution of secondary events such 
as seizures, substantially reduced injury and improved 
behavioural recovery.3 The results of randomised clinical 
trials in full-term infants with moderate-to-severe 
hypoxic ischaemic encephalopathy supported the 
ﬁ nding that mild induced hypothermia consistently 
improved survival and disability, including cerebral palsy 
and neurocognitive outcomes.4 
The challenge is now to improve outcomes for the 
45% of infants who die or survive with disability despite 
mild therapeutic hypothermia. In work in animals, one 
of the most promising add-on agents was the noble 
gas xenon.5 In The Lancet Neurology, Denis Azzopardi 
and colleagues report the results of their multicentre, 
randomised controlled trial,6 which showed that the 
addition of 30% xenon ventilation for 24 h to mild 
hypothermia did not further improve outcomes in 
term infants with hypoxic ischaemic encephalopathy 
compared with mild hypothermia alone. 
The study was well done: the investigators had 
collected strong previous safety data and obtained 
rigorous consent, and randomisation included 
minimisation for disease severity. Their use of MRI 
and magnetic resonance spectroscopy to measure 
outcome is an important innovation, which allowed this 
proof-of-concept study to be completed with roughly a 
tenth of the sample size that would have been needed 
for a pragmatic clinical trial to have 90% power to show 
a 10% improvement. This approach will substantially 
speed up initial testing of potential treatments in future 
trials, although large pragmatic studies will remain 
essential to conﬁ rm the clinical beneﬁ ts of treatments. 
Why did the ﬁ ndings of neuroprotection with 
xenon in animals not translate to human beings? 
The probable reason is not failure of the trial, but 
rather the trial’s setting. Xenon is expensive, and 
necessitates a specialised recirculating ventilator. 
Thus, treatment could not be started by non-specialist 
centres or during transport in the largely outborn 
population. This practical limitation meant that 
initiation of treatment was delayed until a median of 
10 h (IQR 8·2–11·2, range 4·0–12·6)—well outside the 
probable therapeutic period. 
Therapeutic hypothermia needs to be begun within 
roughly 6 h of birth to achieve neuroprotection, and 
earlier initiation—typically 3 h or less after birth3—is 
better for outcomes. Xenon is thought to act though 
anti-excitatory mechanisms, which occur early in the 
cascade leading to delayed cell death. Consistent with 
this hypothesis, Chakkarapani and colleagues7 showed 
an additive eﬀ ect in piglets when xenon treatment 
and mild hypothermia were begun immediately 
after hypoxia–ischaemia. Faulkner and colleagues8 
showed a subadditive eﬀ ect with combined treatment 
started 2 h after hypoxia–ischaemia, such that xenon-
augmented hypothermia reduced cell death and cerebral 
abnormalities (as detected with magnetic resonance 
spectroscopy) compared with normothermia, but not 
compared with mild hypothermia alone. The eﬀ ect of 
delay in treatment with xenon in small animals is variable. 
A study showed an additive beneﬁ t only with immediate 
but not delayed treatment,9 whereas in other studies 
beneﬁ t was noted when treatment was delayed by as 
much as 4–6 h after hypoxia–ischaemia.5 Thus, preclinical 
evidence strongly suggests that xenon needs to be 
started soon after resuscitation to allow neuroprotection, 
and deﬁ nitely within 6 h. Although Azzopardi and 
colleagues reported no apparent eﬀ ects related to timing 
of treatment with xenon, only seven (15%) of 46 infants 
started xenon before 6 h of age.6 
The important message from this trial is that early 
treatment initiation might be as central to studies 
of add-on therapy as it was for the successful clinical 
translation of therapeutic hypothermia. The use of 
rapid, short-term but highly precise outcomes in this 
study is an important innovation that could allow 
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take to complete a single pragmatic trial. More than 
300 years passed from when therapeutic hypothermia 
was ﬁ rst proposed until it was established in clinical 
practice. Further waiting before testing the many 
other promising add-on therapies is not necessary.5 We 
propose that the motto of the neonatal community 
both for when to treat brain injury and for when to 
undertake further clinical trials should be do not delay.
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Opicapone for motor ﬂ uctuations in Parkinson’s disease
Parkinson’s disease is characterised by striatal 
dopamine depletion. The most eﬀ ective treatment 
for the disease is oral levodopa (dopamine’s lipophilic 
precursor) in combination with an aromatic L-amino 
acid decarboxylase inhibitor (to reduce the peripheral 
degradation of levodopa).1 However, long-term 
treat ment with levodopa and decarboxylase inhibitor 
(hereafter referred to as levodopa therapy) is 
complicated by the development of motor ﬂ uctuations 
and dyskinesia.
In The Lancet Neurology, Joaquim Ferreira and 
colleagues address the important question of new 
therapeutic strategies for these motor complications.2 
The complications are thought to be generated by 
the pulsatile, non-physiological stimulation of striatal 
dopamine receptors that normally receive tonic 
stimulation. Accordingly, continuous dopaminergic 
stimulation of the brain’s dopaminergic receptors 
has been suggested to be associated with a lower 
rate of complications than pulsatile dopaminergic 
stimulation.3 Continuous dopaminergic stimulation 
needs a steadier pharmacokinetic proﬁ le and 
more sustained eﬀ ects than those that occur with 
immediate-release levodopa therapy. Catechol-O-
methyltransferase (COMT) is directly involved in the 
metabolism of levodopa and dopamine. Outside the 
CNS, COMT inhibitors increase levodopa’s half-life 
and decrease peak–trough variations in plasma.4 In 
the CNS, COMT inhibitors slow the metabolism of 
dopamine. Two COMT inhibitors have been granted a 
marketing authorisation in Europe and the USA: the 
widely used peripheral COMT inhibitor entacapone 
reduces the time spent in the oﬀ  state for end-of-
dose motor ﬂ uctuations by an average of 41 min and 
is well tolerated, whereas the central COMT inhibitor 
tolcapone reduces this time more  substantially (by 
98 min) but has a poor safety proﬁ le (including 
an increased risk of hepatitis).5 In the context of 
moderate eﬃ  cacy of entacapone and a suboptimal 
proﬁ le of tolcapone, the development of a potent 
third-generation COMT inhibitor with a good safety 
proﬁ le is eagerly awaited.
Ferreira and colleagues have done the ﬁ rst pivotal 
phase 3 study of opicapone (a novel, once-daily 
COMT inhibitor) in a population of 600 patients with 
Parkinson’s disease with motor complications. In 
their superiority analysis, the researchers report that 
14–15 weeks of treatment with opicapone at a dose 
of 50 mg eﬀ ectively reduced the time spent in the 
oﬀ  state (mean diﬀ erence in change from baseline 
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